At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 45 enrolled
Drug / intervention
Docetaxel and Carboplatin AUC 6 +1 moredrug
Likely dose
Docetaxel and Carboplatin AUC 6 75 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Docetaxel, Carboplatin With and Without Low Dose Radiation as Induction Therapy in Locally Advanced Head and Neck Cancer
In Brief
A Phase 2 clinical trial evaluating Low dose fractionated radiation - 80cGy with chemotherapy and Docetaxel and Carboplatin AUC 6 for Head and Neck Cancer and Larynx. Completed, enrolled 45 participants across 1 site.
Detailed Summary
The primary hypothesis of this study is that hyper-radiosensitivity (HRS) seen at extremely low doses of radiation can be exploited to enhance the effect of chemotherapy, and that this effect differs from the cellular effect of higher, standard fractions of radiation used in traditional radiation treatment paradigms.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHead and Neck Cancer, Larynx
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 2014
Enrollment StartOct 2014
Primary CompletionMar 2018
Study CompletionJun 2021
TodayJul 2026
First PostedApr 30, 2014
Enrollment StartOct 1, 2014
Primary CompletionMar 1, 2018
Study CompletionJun 15, 2021
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 12.2 years ago
Interventions
Low dose fractionated radiation - 80cGy with chemotherapyradiation
Chemotherapy + 80 cGy of RT
Docetaxel and Carboplatin AUC 6drug
Docetaxel 75 mg/m2 and Carboplatin AUC 6 without Radiation